Merck & Co. and Imago Biosciences, Inc. have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for approximately $1.35 billion in total equity value.   Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases. Imago’s lead candidate bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor,...